[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOOS-4eajt6eNnlFTCrTpNqboTE6Cp6ZfCuE3EEU-eSM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"Tel Aviv University",[4],95,false,20,2,8689,0,92,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Type 2 Diabetes",9,{"name":18,"count":19},"PTSD",6,{"name":21,"count":22},"Social Anxiety Disorder",4,{"name":24,"count":25},"Anxiety Disorders",3,{"name":27,"count":9},"Social Phobia",{"name":29,"count":9},"Posttraumatic Stress Disorder",{"name":31,"count":9},"Social Anxiety",{"name":33,"count":9},"Anxiety",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,70,95],{"intervention":44,"totalTrials":45,"cells":46},"Liraglutide",1,{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":57},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[],{"trials":58,"activeCount":11},[59],{"nctId":60,"briefTitle":61,"status":62,"phases":63,"primaryCompletion":64,"completion":65,"start":66,"enrollment":67,"conditions":68,"interventions":69},"NCT02783196","Effect of Liraglutide on Clock Genes","UNKNOWN",[41],"2016-12","2017-06","2016-07",14,[15],[44],{"intervention":71,"totalTrials":45,"cells":72},"Empagliflozine",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":74,"activeCount":11},[],{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[85],{"nctId":86,"briefTitle":87,"status":62,"phases":88,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":94},"NCT02918591","Cardiovascular Effects of Empagliflozine",[41],"2018-03","2018-12","2017-11",10,[15],[71],{"intervention":96,"totalTrials":45,"cells":97},"Escitalopram",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":99,"activeCount":11},[],{"trials":101,"activeCount":11},[],{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT03346239","Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety","COMPLETED",[41],"2021-12-01","2018-07-20",105,[21],[96]]